Action Y mAbs Therapeutics - YMAB

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

5,51

Prix Achat

5,01

Prix Vente

6,18

Volume échangé

0,00 Fourchette du Jour 0,00

5,40 Plage de 52 semaines 20,90

Cap du marché

246,788M

Clôture Veille

5,51

Ouverture

Dernière Transaction

5.01

Dernière heure de transaction

11:12:38

Volume financier

VWAP

Volume moyen (3 m)

429 687

Actions en circulation

44 789 076

Rendement du Dividende

Ratio Cours sur Bénéfices

-11,52

Bénéfice par action (BPA)

-0,48

Chiffre d'affairess

84,82M

Bénéfice net

-21,43M

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Its pipeline covers Naxitamab, Omburtamab, GD2-GD3 Vaccine, and others. Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Its pipeline covers Naxitamab, Omburtamab, GD2-GD3 Vaccine, and others.

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

www.ymabs.com

Siège social

Wilmington, Delaware, USA

Fondé

Y mAbs Therapeutics Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker YMAB. Le dernier cours de clôture d'Y mAbs Therapeutics était de US$5,51. Au cours de la dernière année, les actions de Y mAbs Therapeutics ont été négociées dans une fourchette de prix de US$ 5,40 à US$ 20,90.

Y mAbs Therapeutics compte actuellement 44 789 076 actions en circulation. La capitalisation boursière d'Y mAbs Therapeutics est de US$246,79 million. Y mAbs Therapeutics a un ratio cours/bénéfice (ratio PE) de -11.52.

Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:...

Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:...

Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.89	-13.90625	6.4	6.4838	5.4	259810	5.70484497	CS
4	-0.68	-10.98546042	6.19	6.65	5.4	509220	6.02636352	CS
12	-5.21	-48.6007462687	10.72	11.45	5.4	429687	7.03268153	CS
26	-9.55	-63.4130146082	15.06	16.11	5.4	330724	9.85378549	CS
52	-11.12	-66.8671076368	16.63	20.9	5.4	325268	11.78766238	CS
156	-3.16	-36.4475201845	8.67	20.9	2.7	387523	9.19928626	CS
260	-23.65	-81.1042524005	29.16	55.36	2.7	348644	15.53582946	CS

YMAB - Frequently Asked Questions (FAQ)

What is the current Y mAbs Therapeutics share price?

The current share price of Y mAbs Therapeutics is US$ 5,51

How many Y mAbs Therapeutics shares are in issue?

Y mAbs Therapeutics has 44 789 076 shares in issue

What is the market cap of Y mAbs Therapeutics?

The market capitalisation of Y mAbs Therapeutics is USD 246,79M

What is the 1 year trading range for Y mAbs Therapeutics share price?

Y mAbs Therapeutics has traded in the range of US$ 5,40 to US$ 20,90 during the past year

What is the PE ratio of Y mAbs Therapeutics?

The price to earnings ratio of Y mAbs Therapeutics is -11,52

What is the cash to sales ratio of Y mAbs Therapeutics?

The cash to sales ratio of Y mAbs Therapeutics is 2,91

What is the reporting currency for Y mAbs Therapeutics?

Y mAbs Therapeutics reports financial results in USD

What is the latest annual turnover for Y mAbs Therapeutics?

The latest annual turnover of Y mAbs Therapeutics is USD 84,82M

What is the latest annual profit for Y mAbs Therapeutics?

The latest annual profit of Y mAbs Therapeutics is USD -21,43M

What is the registered address of Y mAbs Therapeutics?

The registered address for Y mAbs Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Y mAbs Therapeutics website address?

The website address for Y mAbs Therapeutics is www.ymabs.com

Which industry sector does Y mAbs Therapeutics operate in?

Y mAbs Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
TRIThomson Reuters Corporation	US$ 178,40 (790,66%)	1,51k
ULYUrgent ly Inc	US$ 0,77005 (83,35%)	23,29M
ANNAAleAnna Inc	US$ 11,31 (59,97%)	10
NIXXNixxy Inc	US$ 2,34 (48,10%)	22,08M
CPOPPop Culture Group Company Ltd	US$ 0,9668 (39,71%)	10,5M
TOIIWOncology Institute Inc	US$ 0,0186 (-54,52%)	2
UVSPUnivest Financial Corporation	US$ 21,17 (-29,34%)	6
SPGCSacks Parente Golf Inc	US$ 0,537 (-26,65%)	567,49k
SYTASiyata Mobile Inc	US$ 3,08 (-26,14%)	118,27k
DMRCDigimarc Corporation	US$ 20,00 (-26,04%)	31,03k
ULYUrgent ly Inc	US$ 0,76915 (83,13%)	23,29M
NIXXNixxy Inc	US$ 2,34 (48,10%)	22,08M
VMARVision Marine Technologies Inc	US$ 0,8649 (18,32%)	15,91M
ICCTiCoreConnect Inc	US$ 1,28 (17,43%)	15,06M
CPOPPop Culture Group Company Ltd	US$ 0,9584 (38,50%)	10,51M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Y mAbs Therapeutics Inc (YMAB) Cours

Y mAbs Therapeutics Inc (YMAB)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Y mAbs Therapeutics Inc

YMAB Dernières nouvelles

Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025

Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference

Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025

Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference

Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Form 8-K - Current report

YMAB - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités